Delivery Order 36C10X24D0028-36C10X24N0227

This federal contract award, with ID 36C10X24D0028|36C10X24N0227, is for GERMLINE PGX MOLECULAR TESTING services provided by Fulgent Therapeutics LLC, doing business as Fulgent Diagnostics, a subsidiary of Fulgent Genetics, Inc. The $2,300,000.00 fixed-price contract was awarded by the U.S. Department of Veterans Affairs (VA) Strategic Acquisition Center-Frederick, a civilian agency, with a period of performance through September 30, 2025. The contract has no set-aside designation. Fulgent Therapeutics is an experienced provider of genetic testing and COVID-19 services to various federal agencies, including the VA, Department of Health and Human Services, Department of the Army, and Centers for Disease Control and Prevention. The contract is likely part of a larger effort by the VA to establish nationwide access to advanced genetic testing services, such as oncology, medical genetics, and pharmacogenomic testing, for its patient population.